Skip to content
Screener

Veracyte VCYT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$673.7M-33.0%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$95.33M+8.6%
Castle Biosciences logo
Castle BiosciencesCSTL
$547.81M+9.2%
Personalis, Inc. logo
Personalis, Inc.PSNL
$325.4M+19.1%
Guardant Health logo
Guardant HealthGH
$1.92B+42.5%
Natera, Inc. logo
Natera, Inc.NTRA
$2.66B+51.2%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.8B+72.4%
Enterprise value$3.57B+75.8%
P/E43.1×-40.5×
P/S+2.4×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.001 par value; 125,000,000 shares authorized, 79,791,856 and 79,359,005 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively8079
Additional paid-in capital1,701,4701,695,339
Accumulated deficit(348,923)(377,630)
Accumulated other comprehensive loss(8,221)(8,212)
Total stockholders’ equity1,344,4061,309,576
Total liabilities and stockholders’ equity$1,436,400$1,406,019

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's total liabilities & equity?
Veracyte (VCYT) reported total liabilities & equity of $1.44B in Q1 2026.
How has Veracyte's total liabilities & equity changed year-over-year?
Veracyte's total liabilities & equity increased by 9.2% year-over-year, from $1.32B to $1.44B.
What is the long-term trend for Veracyte's total liabilities & equity?
Over 5 years (2020 to 2025), Veracyte's total liabilities & equity has grown at a 25.2% compound annual growth rate (CAGR), from $457.16M to $1.41B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Veracyte's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude